Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lanreotide Autogel every 14 days in progressive pancreatic or midgut neuroendocrine tumors after prior every-28-day lanreotide
NL-OMON43877Phase 2Active, not recruiting
- Sponsor
- Ipsen
- Start
- Apr 2016
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, open-label trial of lanreotide in islet cell tumor and midgut neuroendocrine tumor (MNET) (2 cohorts), sponsored by Ipsen. Primary endpoint: Median progression-free survival. Started Apr 2016; status: active, not recruiting.
02
Drugs
lanreotide
03
Conditions
islet cell tumormidgut neuroendocrine tumor (MNET)
Beyond the preview
Go deeper on NL-OMON43877.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43877.